Two genetically distinct transgenic breast cancer models have been shown to benefit from therapeutic fucosylation inhibition via 2FF-the TgMMTV-neu (HER2+ luminal B) and the C3(1)-Tag (basal-like) [63]. This evidence concerns the gene ERBB2 and breast cancer.